Lipella Pharmaceuticals Inc. (LIPO) Stock | LIPO Stock Price & Analysis

LIPO

Lipella Pharmaceuticals Inc. LIPO OTC · Healthcare · United States

$0.00 +0.00% +$0.00

Market cap: $2.77K
Enterprise value: -$1.59M
P/E: -
Forward P/E: -
PEG: -
P/S: 0.0x
P/FCF: -
EV/EBITDA: -
ROIC: -308.8%
Gross margin: -1,954.7%
Net margin: -3,069.0%
Dividend yield: -
Payout ratio: -
Net debt/EBITDA: -
Beta: 1.58
Free float: 93.7%

Return vs S&P 500

Period	LIPO	S&P 500	Difference
1 month	0.0%	-2.7%	+2.7 pp
3 months	+200.0%	-2.6%	+202.6 pp
Year to date	-99.7%	+10.9%	-110.6 pp
1 year	-99.9%	+12.7%	-112.6 pp
3 years	-100.0%	+72.1%	-172.1 pp
5 years	-	+62.1%	-
10 years	-	+250.8%	-

Price change, dividends not included.

About the company

Lipella Pharmaceuticals (LPLA) is a biopharmaceutical company specializing in research, development, and commercialization of therapeutic products for the treatment of various diseases, including dermatological and cosmetic indications. The company boasts a broad portfolio of products covering a wide range of patient needs. With a focus on innovation and quality, Lipella Pharmaceuticals strives to bring new and effective therapeutic options to its patients. Lipella Pharmaceuticals (LPLA) shares could be suitable for investors seeking investment opportunities in the biopharmaceutical industry with growth prospects and innovation in healthcare.

Sector

Healthcare

Industry

Biotechnology

CEO

Jonathan Kaufman

Employees

Headquarters

Pittsburgh

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

What speaks for it: Revenue grew by 27% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

What speaks for it: It holds more cash than debt: $1.86M against $264.1K.
What to watch: It passes only 1 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number